CNMD and Ewing sarcoma: At the TUM Children’s Hospital Medical Center München-Schwabing, patients with advanced ES have been treated successfully without side effects utilizing alloreactive TCR transgenic T-cells which targeting ES associated peptides CHM1 and enhancer of zeste homolog 2 (EZH2) presented by non-self MHC [95].